Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of RO5459072 in primary Sjögren's syndrome
2015-004476-30Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing RO5459072 with Placebo (2 arms). Primary endpoint: Clinically relevant decrease in ESSDAI at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
petesicatib
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2015-004476-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004476-30.